Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia

Obes Res. 2003 Feb;11(2):311-2. doi: 10.1038/oby.2003.46.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Obesity Agents
  • Cabergoline
  • Ergolines / adverse effects*
  • Female
  • Humans
  • Hyperprolactinemia / drug therapy*
  • Male
  • Weight Loss*

Substances

  • Anti-Obesity Agents
  • Ergolines
  • Cabergoline